Vitrolife delivered a surprising organic growth recovery with 4% organic growth and even if there was support from larger orders the company is now approaching the low end of its normal organic growth range faster than we expected. Our updated view is a base case valuation of SEK 260 (220), a Bull Case of SEK 400 (365), and a Bear Case of SEK 110 (95).